Form 4: Ginkgo Bioworks Director Receives Stock Units

Ginkgo Bioworks Holdings, Inc. reports that Director Ross Fubini was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026, with vesting conditions tied to continued service.

Summary

• Ross Fubini, a Director at Ginkgo Bioworks Holdings, Inc., was granted 25,000 Restricted Stock Units (RSUs) on June 11, 2026.
• These RSUs represent a contingent right to receive one share of the Issuer's Class A Common Stock per unit.
• The RSUs are scheduled to vest on the earlier of June 11, 2027, or the day immediately preceding the next Annual Meeting after the grant date.
• Vesting is contingent upon Mr. Fubini continuing in his service as a Non-Employee Director through the respective vesting date.
• Following the transaction, Mr. Fubini beneficially owns 25,000 shares of Class A Common Stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard equity grant to a director and does not contain new financial performance data or strategic shifts.

Positives

• Director compensation through equity awards like RSUs can align management interests with shareholder value.
• The grant of RSUs indicates continued confidence in the company's future prospects by its leadership.
• Clear vesting conditions tied to continued service promote director retention and commitment.

Negatives

• The filing does not contain any negative financial or operational information.

Risks

• The value of the RSUs is subject to the market performance of Ginkgo Bioworks' Class A Common Stock.
• Failure to continue in service as a Non-Employee Director through the vesting date will result in forfeiture of the RSUs.
• The vesting schedule is tied to future company events (Annual Meeting), introducing a degree of uncertainty regarding the exact vesting date.

Future Outlook

The RSUs are subject to vesting on June 11, 2027, or the day before the next Annual Meeting, provided the reporting person continues in service as a Non-Employee Director.

Industry Context

StockSavvy.ai notes that the issuance of Restricted Stock Units (RSUs) to directors is a common practice in the biotechnology and synthetic biology sectors, aligning executive incentives with long-term company performance and shareholder value.

Corporate Governance

Related Party Transactions

• The grant of RSUs to Director Ross Fubini is a related party transaction, as it involves compensation to a company insider.

Stakeholder Impact

• Shareholders: The grant of RSUs represents a form of compensation that dilutes existing share ownership, but it also aims to incentivize director performance for long-term value creation.
• Employees: This filing does not directly impact employees, but it reflects the company's compensation structure for its board.
• Management: The filing confirms a standard compensation practice for non-employee directors.

Next Steps

• Director Ross Fubini must continue in service as a Non-Employee Director through the vesting date for the RSUs to vest.
• The RSUs will vest on the earlier of June 11, 2027, or the day immediately prior to the date of the next Annual Meeting.

Key Dates

Keywords

Ginkgo Bioworks, DNA, Form 4, SEC Filing, Restricted Stock Units, RSU, Director Compensation, Equity Award, Beneficial Ownership, Class A Common Stock